Chronic lymphocytic leukaemia-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Chronic lymphocytic leukaemia

Published:2017-01-19 Issue:1 Volume:3 Page:
ISSN:2056-676X
Container-title:Nature Reviews Disease Primers
language:en
Short-container-title:Nat Rev Dis Primers

Author:

Kipps Thomas J.,Stevenson Freda K.,Wu Catherine J.,Croce Carlo M.,Packham Graham,Wierda William G.,O'Brien Susan,Gribben John,Rai Kanti

Publisher

Springer Science and Business Media LLC

Subject

General Medicine

Link

http://www.nature.com/articles/nrdp201696.pdf

Reference213 articles.

1. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. & Stevenson, F. K. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848–1854 (1999).

2. Damle, R. N. et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840–1847 (1999). References 1 and 2 are landmark papers that describe two main subsets of patients with different disease progression tendencies based on IGHV mutation status of the immunoglobulins that are expressed by CLL cells.

3. Tobin, G. et al. Somatically mutated Ig V(H)3-21 genes characterize a new subset of chronic lymphocytic leukemia. Blood 99, 2262–2264 (2002).

4. Ghia, E. M. et al. Use of IGHV3-21 in chronic lymphocytic leukemia is associated with high-risk disease and reflects antigen-driven, post-germinal center leukemogenic selection. Blood 111, 5101–5108 (2008).

5. Kipps, T. J. et al. Developmentally restricted immunoglobulin heavy chain variable region gene expressed at high frequency in chronic lymphocytic leukemia. Proc. Natl Acad. Sci. USA 86, 5913–5917 (1989). This paper describes the discovery that the immunoglobulin repertoire of CLL cells may be highly restricted, suggesting that the antibodies expressed by CLL cells are most likely selected based on their capacity to bind to some common self-antigens.

Cited by 280 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting chronic lymphocytic leukemia with B‐cell activating factor receptor CAR T cells;MedComm;2024-09

2. Focal adhesion kinase as a new player in the biology of onco-hematological diseases: the starting evidence;Frontiers in Oncology;2024-08-30

3. The Novel Anti-Cancer Agent, SpiD3, Is Cytotoxic in CLL Cells Resistant to Ibrutinib or Venetoclax;Hemato;2024-08-27

4. MicroRNA Profiling as a Predictive Indicator for Time to First Treatment in Chronic Lymphocytic Leukemia: Insights from the O-CLL1 Prospective Study;Non-Coding RNA;2024-08-23

5. Real-World Health Care Resource Use and Costs Among Patients With Chronic Lymphocytic Leukemia Treated With Venetoclax-Based and Bruton Tyrosine Kinase Inhibitor–Based Regimens in the Second-Line Setting;JCO Oncology Practice;2024-08

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3